Mani Foroohar
Stock Analyst at Leerink Partners
(3.18)
# 1,142
Out of 5,111 analysts
170
Total ratings
48.98%
Success rate
1.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Outperform | $16 → $20 | $14.11 | +41.74% | 11 | Dec 15, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $85 → $100 | $78.41 | +27.54% | 16 | Dec 15, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $75 → $86 | $75.68 | +13.64% | 16 | Dec 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Market Perform | $370 → $351 | $391.05 | -10.24% | 12 | Dec 15, 2025 | |
| MRNA Moderna | Maintains: Underperform | $15 → $18 | $29.89 | -39.78% | 19 | Nov 21, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $9.72 | +105.76% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $3.42 | +104.68% | 13 | Oct 3, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $22.30 | -55.15% | 2 | Jul 21, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $4.20 | +42.86% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $11.51 | +134.58% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $72 | $19.53 | +268.66% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $6.99 | +143.20% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $67.13 | -27.01% | 11 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $16.41 | +34.06% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $12.46 | +4.33% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $17.94 | +61.65% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $4.81 | -16.84% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $8.36 | +270.81% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.77 | +815.03% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $64.66 | -38.14% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $9.12 | +821.05% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.53 | +176.68% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $26.76 | +187.74% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.02 | +19.64% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $55.97 | +35.79% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.70 | +1,900.00% | 4 | May 12, 2022 |
REGENXBIO
Dec 15, 2025
Maintains: Outperform
Price Target: $16 → $20
Current: $14.11
Upside: +41.74%
Ionis Pharmaceuticals
Dec 15, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $78.41
Upside: +27.54%
BridgeBio Pharma
Dec 15, 2025
Maintains: Outperform
Price Target: $75 → $86
Current: $75.68
Upside: +13.64%
Alnylam Pharmaceuticals
Dec 15, 2025
Maintains: Market Perform
Price Target: $370 → $351
Current: $391.05
Upside: -10.24%
Moderna
Nov 21, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $29.89
Upside: -39.78%
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $9.72
Upside: +105.76%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $3.42
Upside: +104.68%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $22.30
Upside: -55.15%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $4.20
Upside: +42.86%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $11.51
Upside: +134.58%
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $19.53
Upside: +268.66%
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $6.99
Upside: +143.20%
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $67.13
Upside: -27.01%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $16.41
Upside: +34.06%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $12.46
Upside: +4.33%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $17.94
Upside: +61.65%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $4.81
Upside: -16.84%
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $8.36
Upside: +270.81%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.77
Upside: +815.03%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $64.66
Upside: -38.14%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $9.12
Upside: +821.05%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.53
Upside: +176.68%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $26.76
Upside: +187.74%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.02
Upside: +19.64%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $55.97
Upside: +35.79%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.70
Upside: +1,900.00%